Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

The power of context: reconceptualizing the placebo effect.

Miller FG, Kaptchuk TJ.

J R Soc Med. 2008 May;101(5):222-5. doi: 10.1258/jrsm.2008.070466. Review. No abstract available.

2.

Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints.

Camilleri M, Mangel AW, Fehnel SE, Drossman DA, Mayer EA, Talley NJ.

Clin Gastroenterol Hepatol. 2007 May;5(5):534-40. Epub 2007 Apr 11. Review.

PMID:
17428741
3.

Expectations and associations that heal: Immunomodulatory placebo effects and its neurobiology.

Pacheco-López G, Engler H, Niemi MB, Schedlowski M.

Brain Behav Immun. 2006 Sep;20(5):430-46. Epub 2006 Aug 2. Review.

PMID:
16887325
4.

Functional bowel disorders.

Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC.

Gastroenterology. 2006 Apr;130(5):1480-91. Review. Erratum in: Gastroenterology. 2006 Aug;131(2):688.

PMID:
16678561
5.

Personal view: adequate relief as a primary endpoint in irritable bowel syndrome.

Mangel AW.

Aliment Pharmacol Ther. 2006 Apr 1;23(7):879-81. Review.

6.

Sham device v inert pill: randomised controlled trial of two placebo treatments.

Kaptchuk TJ, Stason WB, Davis RB, Legedza AR, Schnyer RN, Kerr CE, Stone DA, Nam BH, Kirsch I, Goldman RH.

BMJ. 2006 Feb 18;332(7538):391-7. Epub 2006 Feb 1.

7.

Neurobiological mechanisms of the placebo effect.

Benedetti F, Mayberg HS, Wager TD, Stohler CS, Zubieta JK.

J Neurosci. 2005 Nov 9;25(45):10390-402. Review. No abstract available.

8.

A course of instruction for women with irritable bowel syndrome.

Bengtsson M, Ulander K, Börgdal EB, Christensson AC, Ohlsson B.

Patient Educ Couns. 2006 Jul;62(1):118-25. Epub 2005 Aug 10.

PMID:
16098703
9.

The placebo effect in irritable bowel syndrome trials: a meta-analysis.

Patel SM, Stason WB, Legedza A, Ock SM, Kaptchuk TJ, Conboy L, Canenguez K, Park JK, Kelly E, Jacobson E, Kerr CE, Lembo AJ.

Neurogastroenterol Motil. 2005 Jun;17(3):332-40.

10.

Diagnostic yield of alarm features in irritable bowel syndrome and functional dyspepsia.

Hammer J, Eslick GD, Howell SC, Altiparmak E, Talley NJ.

Gut. 2004 May;53(5):666-72.

11.

Systematic review: the economic impact of irritable bowel syndrome.

Inadomi JM, Fennerty MB, Bjorkman D.

Aliment Pharmacol Ther. 2003 Oct 1;18(7):671-82. Review.

12.

Validation of irritable bowel syndrome Global Improvement Scale: an integrated symptom end point for assessing treatment efficacy.

Gordon S, Ameen V, Bagby B, Shahan B, Jhingran P, Carter E.

Dig Dis Sci. 2003 Jul;48(7):1317-23.

PMID:
12870789
13.

Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders.

Drossman DA, Toner BB, Whitehead WE, Diamant NE, Dalton CB, Duncan S, Emmott S, Proffitt V, Akman D, Frusciante K, Le T, Meyer K, Bradshaw B, Mikula K, Morris CB, Blackman CJ, Hu Y, Jia H, Li JZ, Koch GG, Bangdiwala SI.

Gastroenterology. 2003 Jul;125(1):19-31.

PMID:
12851867
14.

A signal detection theory analysis of the placebo effect.

Allan LG, Siegel S.

Eval Health Prof. 2002 Dec;25(4):410-20.

PMID:
12449084
15.

A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation.

Novick J, Miner P, Krause R, Glebas K, Bliesath H, Ligozio G, Rüegg P, Lefkowitz M.

Aliment Pharmacol Ther. 2002 Nov;16(11):1877-88.

16.
17.

What are the main methodological problems in the estimation of placebo effects?

Hróbjartsson A.

J Clin Epidemiol. 2002 May;55(5):430-5. Review.

PMID:
12007544
18.

Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome.

Lembo T, Wright RA, Bagby B, Decker C, Gordon S, Jhingran P, Carter E; Lotronex Investigator Team.

Am J Gastroenterol. 2001 Sep;96(9):2662-70.

PMID:
11569692
19.
20.

Adjunctive non-pharmacological analgesia for invasive medical procedures: a randomised trial.

Lang EV, Benotsch EG, Fick LJ, Lutgendorf S, Berbaum ML, Berbaum KS, Logan H, Spiegel D.

Lancet. 2000 Apr 29;355(9214):1486-90.

PMID:
10801169

Supplemental Content

Support Center